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Practical Considerations in Regenerative Medicine Research:
IACUCs, Ethics, and the Use of Animals in Stem Cell Studies

Susan VandeWoude and Bernard E. Rollin

W

hat is the purview of the institutional animal
care and use committee (IACUC) in reviewing
stem cell research?
The intent of US federal laws mandating IACUC review
of animal-related activities was to satisfy contemporary socioethical concerns by introducing deliberations about ethics
and animal welfare into the research process when animals
are used. These laws and the system they chartered have
worked well for the most part in providing opportunities for
consideration of animal welfare as a vital part of animal research. As a result, investigators today are far less naïve
about the ethical issues raised by research on animals and
typically more sympathetic about the need for such consideration. As evidence of this growing awareness, the literature
on and use of analgesia and other modalities for controlling
pain (and, more recently, distress) in research protocols have
grown exponentially, and the issue of environmental enrichment for animals used in research continues to challenge the
research community to consider animal husbandry beyond
uniformity in animal care and the provision of a clean cage
with food and water.

Good Ethics and Bad Ethics
Anyone professionally involved in animal experimentation
knows that IACUC oversight has had a significant impact on
how research is performed. Perhaps less obvious is the role
of the IACUC in helping to educate the general public about
issues that some people believe are matters of ethics but that
in fact are not.
Questions about ethics and morality arise most often
across the range of biotechnological investigations, in a phenomenon that has been dubbed a “Gresham’s Law of ethics”
(Rollin 1995). Gresham’s Law in economics states that “bad
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money drives good money out of circulation.” Thus, for example, in post–World War I Germany, when paper deutschemarks were essentially valueless (vast amounts of currency
were required to buy a loaf of bread), citizens capitalized on
the opportunity to pay off large debts (such as mortgages)
with the valueless currency rather than with gold. With respect to the current topic, Gresham’s Law of ethics refers to
dicta lacking genuine ethical import. Such dicta proliferated
in the absence of the research community’s articulation of
the genuine ethical issues that arose in the wake of genetic
engineering or cloning; examples of these nonethical pronouncements include “cloning violates God’s will” and “genetic engineering desacralizes nature” or “blurs species
boundaries” or “does not show proper respect for the gift of
life.” Since such assertions lack clear meaning, they cannot
be dispatched by simple responses. How, for example, does
one determine the truth of the claim that “cloning violates
God’s will”?
Such inflammatory claims unfortunately play well with a
scientifically illiterate public. That public sees species as fixed
and immutable “natural” kinds and is upset by the rapidity of
change in organisms that can be effected by biotechnology, as
opposed to the slow change traditionally created by natural
and artificial selection. Biotechnology, perhaps more than any
other area of investigation, tends to elicit “Gresham’s Law of
ethics” because it is seen as tinkering with “the very nature of
life.” It may thus raise questions for some IACUC members
that go beyond genuine ethical issues.
However strongly felt, matters that allegedly violate religious principles or metaphysical perspectives should not rise
to the level of ethical issues in a secular society that strives
to separate church and state, as has been discussed in detail
regarding stem cell technology (Rollin 2006). Therefore, we
argue that the general issue of the “ethicality” of stem cell
use, versus specific implications for animal welfare engendered by animal model–based studies, is beyond the
purview of the IACUC insofar as that issue is largely theologically based.
Politicians and political activists have heatedly debated
the morality of stem cell use, resulting in a spate of regulations that may concern the IACUC but do not directly require its oversight. A well-known example is the significant
limitation imposed by recent administrations restricting the
use of fetal tissue for stem cell development. Regardless of
whether this decision is logical based on secular American
societal ethics, it remains a major concern in some quarters.
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Thus the IACUC, perhaps in partnership with the institutional review board (IRB) that reviews research on humans
or internal committees specialized in reviewing research
with human embryonic stem cells, must ensure that researchers scrupulously adhere to all regulations regarding sources
of fetal material. However, it is outside the scope of the IACUC’s charge to debate the “morality” of stem cell research
or to require investigators to address the nuances of public
debate surrounding the origin and sanctity of life if they propose to use stem cells to address a scientific question using
animal models.

•

Chimeras and Clones

•

A significant and problematic spurious issue will arise when
human stem cells, whether derived from fetal tissue or not,
are inserted into an animal, creating a chimeric xenograft.
Although this process is arguably similar to the use of animals to grow human tumors, tissues, or proteins—routinely
practiced in other scientific investigations—the specter of
intermixing species genotypes using primordial germ cells
would predictably be more likely to raise public concerns.
Chimeric entities are, after all, the stuff of nightmares—
gorgons, werewolves, mermaids—and the possibility of creating them raises fear of “the Frankenstein syndrome”
(Rollin 1995). Such research can elicit cries of “mixing
humans and animals,” “debasing human dignity,” “failing to
respect human nature,” and variations on such themes. This
sort of response is, as mentioned, unanswerable in rational
terms, but nonetheless needs to be addressed and the results
of the discussion documented and disseminated.
The use of primordial germ cells to create “clones” of an
animal also raises concerns in certain sectors of society. While
the existence of identical twins might indicate that this phenomenon occurs naturally, and in fact companies have been
founded to preserve genetic material from beloved pets, the
creation of Dolly the cloned sheep sparked much discussion
about the “ethics” of cloning using tissue from adult animals.
Public concern was enflamed by the specter of persons creating genetically identical humans to serve some sinister purpose, but this is the hyperbole of disturbing science fiction.
Again, the debate regarding these issues is beyond the
purview of the IACUC’s regulatory authority. However, since
much research is done with public money and with the permission of the public, scientists cannot be contemptuous or
dismissive of public opinion. While not required by statutory
authority, the IACUC minutes might reflect discussions of
societal concerns, particularly if these involve “hot button”
issues such as those described here, in the hope of clarifying
the difference between real and spurious ethical issues.

Practical Guidelines
Reasonable guidelines (adapted from NRC 2005) suggest
that protocols incorporating the use of human embryonic
stem (hES) cells address the following questions:
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•
•
•

Are hES cells required, or can cells from other primates
or animals or nonembryonic human tissue be used?
Has sufficient animal work preceded the proposed work
involving hES cells?
Might the cell transfer result in the animal’s acquiring
characteristics that are valued as distinctly human?
If hES cells are to be transferred into an animal embryo
or fetus, have studies (for example, with ES cells from
other species or interspecies chimeras) suggested that
the resulting creature would exhibit human characteristics that would be allegedly ethically unacceptable to
find in an animal?
If visible human-like characteristics might arise, have all
those involved in these experiments, including animal
care staff, been informed and educated about this?

Several of these points may have relevance for IACUC or
animal care program oversight of hES experimentation, and
thus are provided here as a point of reference.

Issues Relevant to IACUC Review
The ethical issues associated with stem cell research in the
context of experimental studies using animals concern possible harm, pain, distress, and disease that may accompany
the animal manipulation. For example, standard approaches
to transplanting animal stem cells may require induced or
genetically engineered immunosuppression, creating the
potential for significant morbidity and requiring intensive
monitoring and pharmacological management. The IACUC
therefore must ensure that the investigator has devoted
adequate resources to the monitoring and management of
resulting opportunistic infections or tissue damage related to
cytotoxins or radiotherapy, for example.
Similarly, stem cell therapies are being targeted to treat
diseases that are often severe and debilitating (e.g., diabetes
mellitus, arthritis, and neurodegenerative disorders, as discussed in this issue; Joers and Emborg 2010; Song et al.
2010). Animal model systems designed to evaluate stem cell
therapy interventions for such diseases must replicate the
disease states, which are likely to cause pain and distress in
control animals or in animals for which the therapies are ineffective. Because there are often no modalities for controlling
the pain and distress occasioned by these diseases even in
human patients, the IACUC must consider and weigh the
potential for detection and mitigation of pain and distress in
these animals, and must carefully evaluate experimental endpoints for these studies. In some cases—for example, when
researchers wish to study the full course of the disease—early
endpoints are not an option to curtail suffering (Rollin 1995).
Considerations such as immunosuppression and chronic
disease expression are not unique or specific to stem cell
therapy and have been reviewed elsewhere (e.g., NRC 2008,
2009). Investigators and animal care staff should
•

be aware of potential complications of induced disease,
immunosuppression, and other conditions that may result
in studies involving the use of stem cells in animals,
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•

be able to recognize symptoms that demonstrate animal
pain and distress,
take actions to symptomatically minimize distress associated with sequelae (e.g., provide ready access to food
and water if ambulation is impaired, provide analgesics
if possible, maintain hydration), and
establish well-defined observation frequencies and endpoints for euthanasia in response to anticipated adverse
effects.

•

•

Conclusion
While stem cell experiments raise concerns about the dominion of humans in manipulating animals at the level of the
genome, most of the issues debated in the press and political
arenas about stem cell experiments do not fall under IACUC
regulatory authority. It may be prudent to discuss such issues
when they are presented during protocol review as a matter
of public responsibility, but the primary IACUC issues raised
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by animal experimentation involving stem cells recapitulate
the common issues of animal welfare attendant upon the induction of immunosuppression or chronic diseases.
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